Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 28 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

29%

8 trials in Phase 3/4

Results Transparency

11%

1 of 9 completed trials have results

Key Signals

5 recruiting1 with results

Enrollment Performance

Analytics

Phase 4

7(36.8%)

N/A

6(31.6%)

Phase 2

4(21.1%)

Phase 3

1(5.3%)

Phase 1

1(5.3%)

19Total

Phase 4(7)

N/A(6)

Phase 2(4)

Phase 3(1)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (28)

Showing 20 of 28 trials

NCT07497867Recruiting

Long-term Prospective Study of Korean CADASIL Patients

Role: collaborator

NCT04014803Phase 4Recruiting

Aspirin and a PoTent P2Y12 Inhibitor Versus Aspirin and Clopidogrel in Patients Undergoing PCI for Complex Lesion

Role: collaborator

NCT07324642Phase 1Completed

A Phase 1 MAD Study of KINE-101 in Healthy Volunteers

Role: collaborator

NCT04769362Phase 4Recruiting

Long-term Beta-blocker Therapy After Acute Myocardial Infarction

Role: collaborator

NCT07241143Not ApplicableNot Yet Recruiting

Extra-Peritoneal Tunneling Versus Conventional Drain Fixation After Anterior or Low Anterior Resection

Role: collaborator

NCT03475498Recruiting

A Major Determinant Focused on the ECG or Echocardiogram for PICM and Its Clinical Outcome (PICM Syndrome)

Role: collaborator

NCT05635968Phase 2Completed

The Clinical Trial of Low Dose Irradiation for Alzheimer's Disease

Role: collaborator

NCT07037303Not ApplicableNot Yet Recruiting

Comparing Active Cycle of Breathing Techniques (ACBT) and Aerobika in Treating Bronchiectasis in Korea

Role: lead

NCT03274869Active Not Recruiting

Scrub Typhus Infection Induced Cardiovascular Disease

Role: collaborator

NCT04718935Completed

Nutritional and Metabolic Biomarkers in Prediction of Outcomes After Traumatic Brain Injury: a Patient Cohort Study

Role: collaborator

NCT06138769Phase 2Active Not Recruiting

Lenvatinib After Progression on Atezolizumab-bevacizumab in Hepatocellular Carcinoma

Role: collaborator

NCT02715518Not ApplicableCompleted

FFR Versus Angiography-Guided Strategy for Management of AMI With Multivessel Disease

Role: collaborator

NCT05381194Phase 4Recruiting

BPaL(M) Regimen for the Treatment of MDR/RR-TB

Role: collaborator

NCT05994547Phase 4Completed

Efficacy and Safety of Remimazolam Compared With Midazolam During Bronchoscopy:Randomised Controlled Trial

Role: lead

NCT05770674Not ApplicableUnknown

Comparison of 1 Month vs. 12 Months DAPT in Patients Undergoing PCI With Genoss® DES

Role: collaborator

NCT03748810Completed

Head-to-head Comparison of Empagliflozin and Dapagliflozin

Role: lead

NCT04893148Phase 4Unknown

Efficacy and Safety of iGlarLixi Versus Insulin Glargine Plus Dulaglutide in Patients With Type 2 Diabetes

Role: lead

NCT05103306Unknown

Empagliflozin-based Quadruple Therapy vs Basal Insulin-based Therapy

Role: lead

NCT04647838Phase 2Unknown

Tepotinib in Solid Tumors Harboring MET Alterations

Role: lead

NCT04552574Not ApplicableUnknown

Randomized Clinical Trial of HMR(Home Meal Replacement)-Type Omega-3-balanced-diet

Role: lead